DrugPatentWatch Database Preview
Litigation Details for Shire Development LLC v. Teva Pharmaceuticals USA, Inc. (D. Del. 2017)
» See Plans and Pricing
Shire Development LLC v. Teva Pharmaceuticals USA, Inc. (D. Del. 2017)
| Docket | Start Trial | Date Filed | 2017-11-21 |
| Court | District Court, D. Delaware | Date Terminated | 2019-11-07 |
| Cause | 35:271 Patent Infringement | Assigned To | Richard Gibson Andrews |
| Jury Demand | None | Referred To | Sherry R. Fallon |
| Parties | SHIRE LLC | ||
| Patents | 6,605,300; 6,913,768; 8,846,100; 9,173,857 | ||
| Attorneys | Nathan Roger Hoeschen | ||
| Firms | Morris, Nichols, Arsht & Tunnell | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in Shire Development LLC v. Teva Pharmaceuticals USA, Inc.
The small molecule drugs covered by the patents cited in this case are Start Trial and Start Trial .
Details for Shire Development LLC v. Teva Pharmaceuticals USA, Inc. (D. Del. 2017)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2017-11-21 | 1 | United States Patent Nos. 6,913,768 (“the ’768 patent”), 8,846,100 (“the ’100 patent”), and 9,173,857…(“Shire”), as the record owner of U.S. Patent Nos. 6,913,768, 8,846,100, and 9,173,857.” 46.… This is a civil action for patent infringement arising under the patent laws of the United States, …’857 patent”), attached hereto as Exhibits A, B, and C, respectively (collectively, “the patents in suit…Plaintiff Shire LLC owns the ’768 patent. 38. The ’100 patent, entitled “Controlled Dose Drug | External link to document | |
| 2019-02-27 | 109 | in U.S. Patent Nos. 6,913,768 ('"768 Patent"), 8,846,100 ("'100 Patent"),…construction for multiple terms in U.S. Patent Nos. 6,913,768, 8,846,100, and 9,173,857. Within five days…claim 1 of the ' 100 Patent and claim 1 of the ' 857 Patent. The Patents relate to "a long-acting…quot;It is a bedrock principle of patent law that the claims of a patent define the invention to which …construing patent claims, a court considers the literal language of the claim, the patent specification | External link to document | |
| 2019-06-21 | 184 | Notice of Service | Invalidity Contentions for U.S. Patent No. 8,846,100 and U.S. Patent No. 9,173,857 filed by Actavis Laboratories…2017 8 November 2019 1:17-cv-01696 835 Patent - Abbreviated New Drug Application(ANDA) None | External link to document |
| 2019-11-07 | 205 | Patent/Trademark Report to Commissioner of Patents | the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 6,913,768 B2; 8,846,100 B2; 9,173,857…2017 8 November 2019 1:17-cv-01696 835 Patent - Abbreviated New Drug Application(ANDA) None | External link to document |
| 2017-11-21 | 4 | the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 6,913,768 B2; 8,846,100 B2; 9,173,857…2017 8 November 2019 1:17-cv-01696 835 Patent - Abbreviated New Drug Application(ANDA) None | External link to document | |
| 2019-01-21 | 99 | NOTICE of Lodging of U.S. Patent No. 6,605,300, by Actavis Laboratories FL, Inc., Teva Pharmaceuticals…2017 8 November 2019 1:17-cv-01696 835 Patent - Abbreviated New Drug Application(ANDA) None | External link to document | |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
